Greenberg, H E <br/><br/>
A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.  [electronic resource] 

 -  Journal of clinical pharmacology  Dec 2000 
 - 1509-15 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0091-2700 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aspirin--administration & dosage<br/>Cyclooxygenase 2<br/>Cyclooxygenase 2 Inhibitors<br/>Cyclooxygenase Inhibitors--adverse effects<br/>Double-Blind Method<br/>Drug Interactions<br/>Female<br/>Humans<br/>Isoenzymes--drug effects<br/>Lactones--adverse effects<br/>Male<br/>Membrane Proteins<br/>Platelet Aggregation--drug effects<br/>Platelet Aggregation Inhibitors--administration & dosage<br/>Prostaglandin-Endoperoxide Synthases--drug effects<br/>Sulfones<br/>Thromboxane B2--blood